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Background: The aim of the study was to identify p53 gene mutations by FAMA (fluorescence-assisted mismatch
analysis) in colorectal cancers.
Patients and methods: Analytical scanning of the p53 gene (exons 5–9) was performed in colon cancer samples
from 44 consecutive patients by FAMA. FAMA is a semiautomatic scanning approach based on the chemical cleavage
of the mismatch in fluorescently labeled heteroduplex DNA, obtained from the combination of a normal and a mutated
allele. FAMA has already shown optimal levels of diagnostic accuracy and sensitivity in detecting gene mutations
(nucleotide substitutions, insertions/deletions) both at the germline and somatic level. The peculiar feature of FAMA is
its ability to detect and localize mutations, by a redundant pattern of signals due to fluorescent DNA fragments
generated by chemical cleavage. Moreover, previous data have demonstrated that normal contaminating DNA from
stromal cells in the sample does not affect the sensitivity of the procedure, leading to the identification of the mutation
even when the ratio mutant/normal allele is 10%.
Results: Eighteen mutations (12 missense, one nonsense, two deletions, three nucleotide substitutions at the level of
the splice-junctions) and two polymorphisms were detected by FAMA in 17 patients (39%) and then confirmed by
automated sequence analysis. Six of 18 mutations (33%) were not previously reported for colon cancer samples and
two of 18 lesions (11%) were identified as novel p53 mutations.
Conclusions: Analytical scanning of the p53 gene by FAMA in DNA from colon cancer samples provides a sensitive,
accurate and specific diagnostic procedure for routine clinical application.
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introduction
The occurrence of the inactivation of the p53 tumor suppressor
gene (located in the short arm of chromosome 17 and encoding
for a 53-kD nuclear phosphoprotein) is part of the
chromosomal instability characterizing sporadic cancers and
represents a specific, wide, frequently detected, recurring genetic
event in solid tumors and also a predictive and prognostic
indicator at the clinical level [1–3]. The p53 gene plays
a central role in multiple cellular pathways, being implicated
in the cell cycle control, DNA repair, cell differentiation and
programmed cell death [4–8].
Mutations in the p53 tumor suppressor gene are identified in
approximately 35%–45% [9–12] of colorectal cancers, and it
may be associated with worse prognosis and chemo/
radioresistance [13, 14]. Most of the colon cancer patients
present a B2-C pathologic stage and to date a small but
significant clinical benefit of adjuvant chemotherapy has been
demonstrated in Duke’s C colon cancer, while it is still debated
in Duke’s B2 [15–17]. Thus, the identification of prognostic
and/or predictive molecular parameters, such as p53, represents
one of the most important aims [18–23].
Controversial data exist about clinical implications of p53
alterations, due to the different levels of accuracy of the
diagnostic procedures [24–29].The alterations of the p53 gene
are usually detected by scanning procedures reaching different
levels of accuracy (SSCP, DGGE, DHPLC, CCM) and/or
automated sequencing. The contamination of tumor sample by
genetically normal stromal cells (fibroblasts, endothelial cells,
lymphocytes) represents a very important factor in limiting the
accuracy of diagnostic methods at the somatic level [29] and it
constitutes a critical factor when the molecular diagnosis is
applied in clinical contexts. In this regard, previous data have
demonstrated that most of the diagnostic techniques are not
sensitive when the contaminating normal DNA is more than
20% of the total content of the sample. In particular, direct
sequencing fails to identify a mutation (nucleotide substitution)
when more than 16% of normal contaminating DNA is present
in the sample [27, 30].
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FAMA is a semiautomatic scanning approach based on the
chemical cleavage of the mismatch in fluorescently labeled
heteroduplex DNA, obtained from matching a normal and
a mutated alleles. The normal DNA drives all mutant DNA into
hybridization, thus permitting the heteroduplexes formation.
The subsequent chemical cleavage of the mismatch and the
formation of shorter fluorescent DNA extra fragments define
the mutation. Thus, the FAMA diagnostic approach is not
affected by normal DNA contamination, which is usually
present when a molecular diagnosis at the somatic level is
performed, but, on the contrary, it takes advantage and fails to
detect mutation at normal allelic rate £8%. In addition,
a peculiar feature of FAMA is the ability to detect, precisely
locate and define genetic mutations, even if multiple and
different, along the same fluorescent DNA fragment up to 1.3 kb
in length [30, 31]. Therefore, molecular scanning of p53 gene by
FAMA represents one of the most accurate and sensitive
diagnostic procedures. In this study, FAMAwas performed in 44
tumor samples in order to evaluate better the spectrum of p53
mutations in colorectal cancer.
patients and methods
samples and DNA extraction
Forty-four samples of primary colorectal cancer from surgically treated
patients followed at the San Salvatore Hospital of L’Aquila were
consecutively collected and then analyzed for p53 gene mutations. Tumor
samples were stored at 80C at the time of surgery. After histologic
confirmation of colorectal carcinoma, genomic DNA was extracted,
Figure 1. p53 gene amplicons for F.A.M.A.
Table 1. p53 mutations in colon cancer by FAMA
Samples Exon Nu. Change AA change Type IARC database
Colon Other cancers
C94 5 GCC 13065 GGC Ala 129 Gly Missense Not reported Not reported
C17 5 CAA13094 CCA Gln 136 Pro Missense Not reported Reported
C1 5 GAG 13189 CAG Glu 171 Gln Missense Reported Reported
C118 5 CGC 13203 CAC Arg 175 His Missense Reported Reported
C125 5 CGC 13203 CAC Arg 175 His Missense Reported Reported
C122 5 TGC 13207 TGG Cys 176 Trp Missense Not reported Reported
C36 6 CAG 13334 TAG Arg 192 Stop Nonsense Reported Reported
C38 6 13370 del G Val 204 Deletion Not reported Reported
S.j. AG gtc 13434 AG gcc Splice junction Reported Reported
int 6 cgc 13965 ccc Polymorphism
C5 S.j. AG gtc 13434 AG gcc Splice junction Reported Reported
C106 S.j. AG gtc 13434 AG gcc Splice junction Reported Reported
C22 7 14030 del A Asn 235 Deltion Not reported Not reported
C85 7 GGC 14060 AGC Gly 245 Ser Missense Reported Reported
C112 7 CGG 14070 CTG Arg 248 Leu Missense Reported Reported
C70 7 ATC 14069 ACC Ile 247 Thr Missense Not reported Reported
C30 8 CTG 14463 CCG Leu 265 Pro Missense Reported Reported
C39 8 CGG 14513 TGG Arg 282 Trp Missense Reported Reported
C127 8 CGG 14513 TGG Arg 282 Trp Missense Reported Reported
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according to the proteinase K digestion and phenol/chloroform
extraction protocol.
detection of p53 gene mutations
Analytical scanning of the p53 core domain (exons 5–9) was planned by
FAMA, a semiautomatic scanning procedure based on the chemical cleavage
of mismatch of heteroduplex DNA molecules, which has demonstrated
optimal diagnostic accuracy even for large PCR fluorescent amplicons
(up to 1.3 kb in length) [31, 32]. P53 core domain was analyzed using two
fluorescent amplicons (Figure 1), as previously reported by our group [30]:
p53.1, 1264 bp, spanning exons 5–7 and adjacent introns and p53.2, 831 bp,
spanning exons 8–9 and flanking introns. Fluorescent primer pairs
conjugated at the 59-end with FAM (sense strand) and HEX (antisense
strand) fluorophores were used [30]. All primers were selected within
intronic DNA sequence, at least 100 nucleotides apart from exons, and
contained a ‘GG’ dinucleotide at the 59-end as a spacer between the
fluorophore and the DNA sequence: p53.1 forward /59-FAM-
GGTTGCAGGAGGTGCTTACA-39; p53.1 reverse /59-HEX-
GGTATGGAAGAAATCGGTAAGA-39; p53.2 forward /59-6-FAM-
GGTCATCACATTTCCGGCGG-39; p53.2 reverse /59-HEX-
GGAAGTAACTCCATCGTAAGTC-39. PCR reactions (35 cycles: 309, 94C;
309, 56C; 1.209, 72C) were performed using 200 ng of genomic DNA;
10 pmoles of fluorescent primers, 1 · PCR buffer (50 mM Tris pH 9.2,
16 mM (NH4)2SO4, 2.25 mM MgCl2), Taq DNA polymerase 1.25 IU, in
a total volume of 25 ll. Then heteroduplex formation and chemical
cleavage reactions were carried out as previously described [31, 32]. The
electrophoresis was performed on an Applied Biosystems ABI PRISM 377
DNA sequencer. The electrophoresis results were analyzed using the
GeneScan 3.1 software. All mutations observed by FAMA were confirmed by
direct sequencing, using the Big Dye Terminator Ready Reaction premix
(Applied Biosystems) according to the manufacturer’s instructions. Each
sample was amplified and 50 ng were then purified and used for sequencing
reactions, using both upstream and downstream primers. The following
primer pairs, specific for exons 5, 6, 7 and 8–9 were used: p53.1 forward,
p53.1 reverse, p53.2 forward and p53.2 reverse as previously described, but
not containing the fluorophore at the 59 end; and p53.5 reverse, p53.6
forward, p53.6 reverse, p53.7 forward as already described. In some case,
mono-allelic sequencing was performed by subcloning single alleles using
‘pGEM-T easy vector’ (Promega, madison, WI), according to the
manufacturer’s instructions.
results
Analytical scanning by FAMA of the p53 gene (exons 5–9) was
performed in 44 colorectal cancer samples. Table 1 describes the
18 p53 mutations detected in 17 patients (39%), one patient
showed a double p53 gene mutation. The mutation distribution
in the exons subjected to analysis was: exon 5, 6 (33%); exon 6, 2
(11%); exon 6 splice-site, 3 (17%); exon 7, 4 (22%); exon 8, 3
(17%). Twelve missense (67%), one nonsense (5%), three splice
site mutations (17%) and two microdeletions (11%) generating
an early stop codon were found. Six mutations (35%) were
ascribed to hot spot regions: codon 175, 2; codon 245, 1; codon
248, 1; codon 282, 2. The splice site mutation was observed in
three samples. Overall, 14 different mutations were observed.
Two novel p53 mutations were identified in this study: exon 5,
C13065G (Ala 129 Gly); exon 7, 14030 delA, generating an early
stop codon (Table 2). Six of the identified mutations were never
reported in colon cancer samples.
A missense mutation (C122 sample) never reported in
colorectal cancer (C13207G, Lys 176 Trp) is shown in Figure 2.
Extra bands are displayed in the gel file (Figure 2A) due to
fluorescent heteroduplex DNAs subjected to chemical cleavage
that are also identified by peaks in the electropherogram’s plots
(Figure 2B, C), specifically defining the position and the nature
of the mutation. The two extra bands in the electrophoretic lane
of the sample treated with hydroxylamine indicate a couple
of differentially labeled DNA fragments obtained by the
chemical cleavage of sense (261 nt, blue, marked with FAM)
and antisense (1003 nt, green, marked with HEX) strands, which
represent the specific signature of a C/G substitution.
Interestingly, the samples C38 (Figure 3) showed a couple of
extra bands, characterizing the specific signature of two different
mutations as well as an intronic polymorphic variant in the
same p53.1 amplicon. The extra fragments marked with FAM
(blue, sense strand) fluorophore on HA and OT lane (Figure 3A,
B, D), 491 nt in length, are due to a T>C nucleotide substitution
at the level of the donor splice junction of exon 6 (Figure 3A, C,
D). The extra fragments in the gel file (Figure 3A) marked with
FAM (blue, sense strand) on the OT lane and with HEX (green,
antisense strand) on HA lane, each 421 nt and 843 nt in length
(Figure 3A, C, D), respectively, describe a 13370 delG mutation
within the exon 6, as confirmed by mono-allelic sequencing
(Figure 3F). Moreover, the extra fragments in the HA lane,
Table 2. Mutation features
N % IARC
database
%
Novel
mutations
Samples 44
Wild-type 27 61
Mutant 17 39 43.6
Mutation type
Missense 12 67 73 3
Nonsense 1 5 7
Splice junction 3 17 2
Deletion 2 11 9 2
Substitutions
A:T>C:G 1 5 4
A:T>G:C 3 16 11
A:T>T:A 0 0 5
G:C>A:T 6 36 44
G:C>C:G 3 16 7
G:C>T:A 1 5 15
Exon mutation distribution
Exon 5 6 33 33 2
Exon 6 2 11 8 1
Exon 7 4 22 29 2
Exon 8 3 17 25 0
Exon 9 0 0
Splice junction 3 17
Hot spot
175 2 11 14
245 1 5 6
248 1 5 13
273 0 0 7.5
282 2 11 6
Total 6 35 23
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marked with FAM and HEX fluorophores, respectively 1020 and
244 nt in length (Figure 2A), describe a polymorphic variant
within the intron 6 (cgc 13965 ccc). The last two sequence
variants were also confirmed by automated sequencing (Figure 3).
discussion
The analytical scanning of the p53 gene performed by FAMA in
44 colorectal cancer DNA samples confirms that FAMA is
a feasible procedure for molecular diagnosis of both germline
and somatic mutations [32, 33]. The redundancy of signals
obtained by the chemical cleavage, even in the presence of a low
mutant/normal allele ratio (around 10%), makes it suitable for
identifying exactly both the nature and the position of the
genetic lesion. The p53 core domain was examined by scanning
only two long fluorescent amplicons containing exons 5–9 and
flanking introns. The rate of mutation was 39% (17/44),
according to that reported in the IARC database R10 (43%,
range 5%–100%; CI 31% to 55%, median p53 mutations),
which shows all known p53 mutations identified with different
diagnostic procedures. In addition, the rate of the different types
of mutations detected in this study was equivalent to that
reported in the IARC database (missense 66.6% versus 73%
IARC, deletions 11% versus 9% IARC, nonsense 5% versus 7%
IARC). A stronger incidence of splice-junction mutations was
detected (17% versus 2%), most probably due to the diagnostic
strategy as well as to the primers selected far from the exon
splice-site. Interestingly, two novel 53 mutations were identified:
one deletion (exon 7, 14030 delA, generating an early stop
codon) and one missense (exon 5, C13065G; Ala 129 Gly)
unreported in the IARC database (last updated July 2005).
Overall, FAMA detected two unreported mutations in all type
of cancer (2/14; 14%) and six unreported mutations in colon
cancer (6/14; 43%). In conclusion, the analysis by FAMA of
Figure 2. Sample C38. (A) Gel imageof samples C38 and C49 (control) : in black polimorphism and T stretch FAMA signal; in red mutation at codon 204
(13370 del G) FAMA signal; in blue mutation at splice site (AG gtc 13434 AG gcc) FAMA signal (B) F.AM.A. Electropherogram of sample treated with
HA (sense strand); (C) F.AM.A. Electropherogram of sample treated with HA (antisense strand); (D) F.AM.A. Electropherogram of sample treated with
OT (sense strand); (E) F.AM.A. Electropherogram of sample treated with OT (antisense strand); F Automated mono-allelic sequencing of a wt allele;
G Automated mono-allelic sequencing of the mutans allele.
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colon cancer DNA samples has confirmed its diagnostic
accuracy at the somatic level, even in detecting multiple
sequence variants in the same amplicon, with consequent time
reduction of the molecular analysis.
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